FDA Approves Risk Evaluation and Mitigation Strategy for Extended Release and Long Acting Opioid Medications
Published: Jul 11, 2012
The U.S. Food and Drug Administration (FDA) recently approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications. ER/LA opioids are highly potent drugs that are approved to treat moderate to severe persistent pain for serious and chronic conditions. The misuse and abuse of these drugs have resulted in a serious public health crisis of addiction, overdose, and death.
Want to read the full alert and receive alert emails?
